Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States
Lauren Ramjee,1 Nesrin Vurgun,1 Christopher Ngai,2 Mit Patel,3 Gabriel Tremblay1 1Health Economics & Outcomes Research (HEOR), Cytel, Inc, Waltham, MA, USA; 2Market Access, Calliditas NA Enterprises, New York, NY, USA; 3Health Economics & Outcomes Research (HEOR), Calliditas NA Enterprises,...
Saved in:
Main Authors: | Ramjee L (Author), Vurgun N (Author), Ngai C (Author), Patel M (Author), Tremblay G (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2023-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insights on Nefecon®, a Targeted-Release Formulation of Budesonide and Its Selective Immunomodulatory Effects in Patients with IgA Nephropathy
by: Barratt J, et al.
Published: (2024) -
Association between the ACYP2 Polymorphisms and IgAN Risk in the Chinese Han Population
by: Gang Jin, et al.
Published: (2019) -
Analysis of a Familial IgAN Accompanied by COL4A3 Mutation
by: Lin SQ, et al.
Published: (2024) -
APOC1 exacerbates renal fibrosis through the activation of the NF-κB signaling pathway in IgAN
by: Kuipeng Yu, et al.
Published: (2023) -
Incidence, demographic, biochemical, and clinicopathological profile of primary IgAN in a tertiary care center from Northern India
by: Mohammad Ashraf Bhat, et al.
Published: (2022)